Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Aug 9;77(6):556-63.
doi: 10.1212/WNL.0b013e318228bf11. Epub 2011 Jul 27.

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

M Sano  1 , K L Bell, D Galasko, J E Galvin, R G Thomas, C H van Dyck, P S Aisen
Affiliations
Randomized Controlled Trial

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

M Sano et al. Neurology. .

Abstract

Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) may decrease the risk of Alzheimer disease (AD) and a single-site trial suggested possible benefit in cognition with statin treatment in AD, supporting the hypothesis that statin therapy is useful in the treatment of AD.

Objective: To determine if the lipid-lowering agent simvastatin slows the progression of symptoms in AD.

Methods: This randomized, double-blind, placebo-controlled trial of simvastatin was conducted in individuals with mild to moderate AD and normal lipid levels. Participants were randomly assigned to receive simvastatin, 20 mg/day, for 6 weeks then 40 mg per day for the remainder of 18 months or identical placebo. The primary outcome was the rate of change in the Alzheimer's Disease Assessment Scale-cognitive portion (ADAS-Cog). Secondary outcomes measured clinical global change, cognition, function, and behavior.

Results: A total of 406 individuals were randomized: 204 to simvastatin and 202 to placebo. Simvastatin lowered lipid levels but had no effect on change in ADAS-Cog score or the secondary outcome measures. There was no evidence of increased adverse events with simvastatin treatment.

Conclusion: Simvastatin had no benefit on the progression of symptoms in individuals with mild to moderate AD despite significant lowering of cholesterol.

Classification of evidence: This study provides Class I evidence that simvastatin 40 mg/day does not slow decline on the ADAS-Cog.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow of participants
Figure 2
Figure 2. Effect of treatment on the primary outcome measures
Mean of ADAS-Cog = Alzheimer's Disease Assessment Scale–cognitive portion total score (A) and change score (B) by treatment and visit. Presented with 95% confidence intervals.
See this image and copyright information in PMC

Comment in

References

    1. Hartmann T, Kuchenbecker J, Grimm MO. Alzheimer's disease: the lipid connection. J Neurochem 2007;103 (suppl 1):159–170 - PubMed
    1. Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer's disease: epidemiological evidence. Acta Neurol Scand Suppl 2006;185:50–57 - PubMed
    1. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity: The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009;80:13–17 - PubMed
    1. Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004;63:1624–1628 - PubMed
    1. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer's disease, change in cognitive function, and neuropathology. Neurology 2008;70:1795–1802 - PubMed

Publication types

MeSH terms